Guides for diagnostic development

Getting a new diagnostic test reimbursed

Getting paid takes three separate wins: a billing code, a coverage decision and a payment rate. FDA clearance and a CLIA license make a test legal to offer, but guarantee none of the three. Plan reimbursement in parallel with development, because payers judge the evidence you generate.

The three wins

Coding, coverage, payment

Step 1

Coding

A billing code that identifies your test on a claim.

Step 2

Coverage

A payer's decision that the test is medically necessary for certain patients.

Step 3

Payment

The amount the payer pays per test, set for Medicare through the Clinical Laboratory Fee Schedule.

1. Coding

Give the test a billing code

  • CPT Category I: standard codes for a method or analyte, used by many labs, such as molecular pathology Tier 1 and 2 codes.
  • CPT PLA code: a Proprietary Laboratory Analyses code for one specific test, for proprietary tests with no fitting Category I code.
  • Unlisted code: a catch-all such as 81479. Short-term only; payment is unpredictable.
  • DEX Z-Code: a registry identifier tying your test to your lab. Not a billing code on its own, but required with the CPT code by Medicare MolDX contractors and some commercial payers.
PLA codes are often the fastest route. The AMA accepts applications all year from the CLIA-certified lab performing the test or the maker of an FDA-cleared or approved kit. The test must already be commercially available in the US, and you submit its full SOP; algorithm-only analyses do not qualify. Applications are reviewed quarterly and new codes take effect the quarter after publication. The AMA approved a dedicated PLA code for PromarkerD, Proteomics International's diabetic kidney disease test, announced jointly with ResearchDx.

2. Coverage

Convince payers the test is medically necessary

  • National Coverage Determinations apply across Medicare. NCD 90.2, for example, covers FDA-approved NGS companion diagnostics in advanced cancer.
  • Local Coverage Determinations are written by the Medicare Administrative Contractor for the region where your lab is located.
  • MolDX, run by Palmetto GBA since 2011, handles molecular tests for several contractors. Register the test in the DEX registry for a Z-Code, then submit a technical assessment of your published data; Palmetto decides clinical utility, coverage and pricing. Claims without the Z-Code are rejected.
  • Commercial payers publish their own medical policies, often guided by Medicare decisions and society guidelines such as NCCN. Some, such as UnitedHealthcare, also require Z-Codes.
  • State biomarker testing laws in a growing number of states require some insurers to cover biomarker tests backed by FDA approval, Medicare coverage or national guidelines.

3. Payment

Set the price

Medicare pays lab tests from the Clinical Laboratory Fee Schedule. For a new code, CMS holds an annual public meeting where labs present data on what the test should be paid. An advisory panel then recommends a crosswalk, pricing the test like a similar existing one, or gapfill, where contractors set local prices that CMS turns into a national median when no comparable test exists. CMS posts preliminary decisions in September and finalizes them in November, with a 60-day window for reconsideration. Gapfill takes roughly nine months longer but can better reflect the cost of a truly novel test.

Advanced Diagnostic Laboratory Tests (ADLTs) are a special category for single-lab tests that combine multiple DNA, RNA or protein biomarkers with a unique algorithm, or that are FDA-cleared or approved. ADLT status brings a different payment basis, starting with the lab's list price for an initial period.

PAMA and 2027 rates. Fee schedule rates follow what private payers paid. Labs reported 2025 private-payer data in 2026; new rates take effect January 1, 2027, with cuts of up to 15% a year possible through 2029. As of November 2026 the RESULTS Act, which would freeze rates and limit future cuts, had not passed. Check the current rate before building a business case.

Evidence

The evidence payers want

Does the test measure accurately?

Analytical validity

Your CLIA or FDA validation: accuracy, precision and detection limits.

Does the result track the condition?

Clinical validity

Clinical studies reporting sensitivity, specificity, predictive values or risk.

Does using it improve care?

Clinical utility

Studies showing changed decisions, better outcomes or savings; guideline inclusion; health-economic models.

Clinical utility is usually the hardest to show. Publish in peer-reviewed journals, since most technical assessments and medical policies only weigh published data, and design studies in the population the payer covers.

Roadmap

What to do, and when

  1. During development: define the intended use and the patients a payer would cover; map the evidence payers will want and design clinical studies to produce it.
  2. During validation: validate analytically to a standard that supports a technical assessment and, if planned, an FDA submission.
  3. At launch: register in DEX for a Z-Code if you bill molecular tests to MolDX or Z-Code payers, and apply for a PLA code once the test is commercially available.
  4. First year: present at the fee schedule annual public meeting, submit the MolDX technical assessment or LCD request, and approach key commercial payers with your published evidence.
  5. Ongoing: publish clinical utility data, seek inclusion in society guidelines, and track denials to find gaps in your evidence.

Sources: AMA, CPT PLA codes · Noridian, MolDX · CMS, CLFS annual public meetings · ADLM, PAMA reform (Aug 2026) · ADS, lab reimbursement review (Nov 2026)

Bringing a new test to market?

We develop and validate tests, run them in our CLIA/CAP laboratory, and support the evidence and submissions payers need.